Monocyte Inflammatory Signaling

+CD16+ monocytes (intermediate and non-classical), which are associated with the thickness of the coronary fibrous cap in atherosclerotic lesions. 6 On the other hand, in patients with stable angina, CD14+CD16+ was shown to be associated with the vulnerability of atherosclerotic plaque. 7 These laboratory data are of paramount importance for the management of these patients, and it has been observed that CD14+CD16+ monocytes have a greater capacity to interact with endothelial cells, greater ability to present antigens, and increased expression of inflammatory cytokines compared to CD14+CD16+. 5 These findings demonstrate that CD14++CD16+ monocytes are associated with cardiovascular disease and the progression and instability of atherosclerotic plaque. These data will increase the understanding of the current state of patients with atherosclerosis in the therapeutic and temporal management of the current inflammatory state. For